| 1.14 -0.1 (-8.06%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.51 | 1-year : | 1.66 |
| Resists | First : | 1.3 | Second : | 1.42 |
| Pivot price | 1.22 |
|||
| Supports | First : | 1.1 | Second : | 0.91 |
| MAs | MA(5) : | 1.2 |
MA(20) : | 1.24 |
| MA(100) : | 1.57 |
MA(250) : | 6.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 25 |
D(3) : | 29.1 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 20.39 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIVI ] has closed below the lower bollinger band by 18.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BIVI ] is to continue within current trading range. It is unclear right now based on current values. 58.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.24 - 1.25 | 1.25 - 1.25 |
| Low: | 1.11 - 1.11 | 1.11 - 1.12 |
| Close: | 1.11 - 1.12 | 1.12 - 1.13 |
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Fri, 16 Jan 2026
BioVie hits enrolment milestone in early Parkinson’s trial, data due later this year - Proactive financial news
Thu, 08 Jan 2026
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease - Yahoo Finance
Wed, 24 Dec 2025
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Thu, 11 Dec 2025
What Makes BioVie (BIVI) a New Buy Stock - Yahoo Finance
Thu, 20 Nov 2025
Biotech Stocks Swing After Hours: Delcath Rises On Buyback, BioVie And Cassava Rebound - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 17.8 (%) |
| Shares Short | 171 (K) |
| Shares Short P.Month | 168 (K) |
| EPS | -6.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.1 % |
| Return on Equity (ttm) | -94.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|